Roche strongly outperforms market in first quarter

Genentech transaction completed, integration proceeding rapidly

Roche Group

Group sales up 8% in local currencies and 7% in Swiss francs to 11.6 billion Swiss francs (-1% in US dollars)

Roche completes transaction to take full ownership of Genentech — key decisions on organisational structure and management appointments taken

Full-year outlook to be updated to include impact of Genentech transaction and communicated with half-year resultsPharmaceuticals Division

Pharmaceuticals Division
• Sales advance 8% in local currencies and Swiss francs – around twice as fast as the global market –driven by key products in the oncology, virology, ophthalmology and inflammation portfolios
• Encouraging response to rollout of RoActemra for rheumatoid arthritis in first EU countries
• MabThera receives EU approval as first-line treatment for chronic lymphocytic leukemia
• FDA advisory panel unanimously supports use of Avastin in patients with previously treated glioblastoma brain cancer
• Results of phase III trial of Herceptin in HER2-positive inoperable stomach cancer (ToGA) released a year earlier than expected due to significant overall survival benefit

Diagnostics Division
• Divisional sales grow 8% in local currencies and 3% in Swiss francs, well ahead of the global market
• Professional Diagnostics and Tissue Diagnostics are key growth drivers
• Acquisition of innovatis strengthens Roche Applied Science’s cell analysis portfolio
 

Basel,  Switzerland, 16 April 2009-- Commenting on the first three months of 2009, Roche CEO Severin Schwan said: ‘With growth of 8%, the Roche Group’s sales developed very well in the first three months of 2009. Sales in both divisions continued to grow significantly faster than their respective markets. We are therefore confident that we can achieve our full-year targets. Following the friendly merger agreement with Genentech and rapid completion of the transaction, we have made considerable progress with integration activities. We are delighted that Art Levinson will continue to support us in an active role and that many outstanding individuals from both Genentech and Roche have committed themselves to driving forward the combined businesses. We will update our full-year outlook to include the impact of the Genentech transaction when we announce our halfyear results.’

For full report link to http://www.roche.com/med-cor-2009-04-16-e.pdf

Posted: April 2009


View comments

Hide
(web5)